Human Formulations

Mefenamic Acid 500 mg + Dicyclomine HCl 20 mg Uncoated Tablet

Mefenamic Acid 500 mg + Dicyclomine HCl 20 mg Uncoated Tablet is a uncoated tablet formulated with Mefenamic Acid 500 mg + Dicyclomine HCl 20 mg. The active ingredient profile is Mefenamic Acid; Dicyclomine HCl, placing the product in the nsaid + antispas

TabletsNon-Beta-Lactam Tablets Single Ingredient Uncoated Tablet
Sterile injectable formulation

Product information

Product Line
Human Formulations
Category
Tablets, Non-Beta-Lactam Tablets
Dosage Form
Uncoated Tablet
Product Type
Single Ingredient

Available strengths

Mefenamic Acid 500 mg + Dicyclomine HCl 20 mg

Description

Mefenamic Acid 500 mg + Dicyclomine HCl 20 mg Uncoated Tablet is a uncoated tablet formulated with Mefenamic Acid 500 mg + Dicyclomine HCl 20 mg. The active ingredient profile is Mefenamic Acid; Dicyclomine HCl, placing the product in the nsaid + antispasmodic combination category. The formulation combines an antispasmodic component with an analgesic or NSAID component for selected painful spasm-related conditions. The uncoated presentation is an oral solid-dosage form and should be described according to the approved finished-product specification. For website cataloguing, composition, strength, dosage form and release/coating characteristics should be displayed prominently and consistently. The description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and the prescriber’s judgement. Prescription status, precautions, interactions, adverse effects and dosing must be checked against the current approved product label before publication. Manufacturer, licence, storage, shelf-life, pack configuration and market-specific regulatory details should be added only from verified product documentation.
WHO-GMP Sourced
Sterile Supply
Regulatory Documentation
Quality Assured